Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) Files An 8-K Submission of Matters to a Vote of Security Holders

Item5.07

On May8, 2017, Aquinox Pharmaceuticals, Inc. (the Company) held
its 2017 Annual Meeting of Stockholders at the offices of Cooley
LLP at 1700 Seventh Avenue, Suite 1900, Seattle, Washington,
98101 (the Annual Meeting). At the Annual Meeting, the Companys
stockholders voted on two proposals, each of which is described
in more detail in the Companys definitive proxy statement on
Schedule 14A filed with the Securities and Exchange Commission on
March28, 2017. The following is a brief description of each
matter voted upon and the certified voting results with respect
to each matter.

Proposal No.1. Stockholders elected each of the three nominees
for Class III director to serve until the Companys 2020 Annual
Meeting of Stockholders and until his respective successor has
been duly elected and qualified, or, if sooner, until the
directors death, resignation or removal. The final voting results
were as follows:

Proposal No.2. Stockholders ratified the selection by the Audit
Committee of the Companys Board of Directors of Deloitte LLP as
the Companys independent registered public accounting firm for
the fiscal year ending December31, 2017. The final voting results
were as follows:

About Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP)

Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company operates in the segment of identification and development of therapeutics in disease areas of inflammation and immuno-oncology. Its primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells. The Company’s product candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. The Company is developing AQX-1125 as a treatment in interstitial cystitis/bladder pain syndrome (IC/BPS), a chronic inflammatory disease of the bladder. It has completed and reported results from its Leadership trial, which is a multicenter, randomized, double-blind, placebo-controlled, Phase II clinical trial.

Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) Recent Trading Information

Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) closed its last trading session down -0.31 at 14.58 with 200,065 shares trading hands.